June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Efficacy of Avastin Step-Therapy for Age-Related Macular Degeneration
Author Affiliations & Notes
  • Jonathan Siktberg
    Vanderbilt University School of Medicine, Nashville, Tennessee, United States
  • Stephen J Kim
    Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Shriji Patel
    Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Footnotes
    Commercial Relationships   Jonathan Siktberg, None; Stephen Kim, None; Shriji Patel, ALCON (F)
  • Footnotes
    Support  Supported by an Unrestricted Departmental Award from Research to Prevent Blindness
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4197. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jonathan Siktberg, Stephen J Kim, Shriji Patel; Efficacy of Avastin Step-Therapy for Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4197.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Given the high costs of FDA-approved anti-VEGF agents for exudative age-related macular degeneration (nAMD), step-therapy requiring initial treatment with bevacizumab is being proposed nationally. Controversy exists regarding the efficacy and cost-effectiveness of such a protocol. Beginning in January 2012, Vanderbilt Eye Institute (VEI) initiated a treatment algorithm for nAMD beginning with bevacizumab. We performed a retrospective cohort study of patients treated under this protocol to investigate the efficacy of bevacizumab step-therapy.

Methods : We analyzed the clinical course of patients meeting the inclusion criteria of undergoing initial treatment within the nAMD step-therapy protocol at VEI with at least 3 consecutive monthly injections of Avastin (bevacizumab, Genentech) from January 2012 to August 2018. Patients were excluded if they had past intraocular surgery other than routine cataract surgery. Of the 257 patients in the original VEI database, 124 patients were eliminated due to inclusion and exclusion criteria. The study population is 133. Age range is 59-106. The primary outcome was defined as the success rate of Avastin therapy. Treatment success was defined as achieving a stable injection regimen without recurrence of neovascular disease, loss of 3 or more Snellen chart lines, or requirement of switching to an FDA-approved anti-VEGF agent.

Results : Of 133 patients, 106 (80%) achieved treatment stability on Avastin. 70 patients (53%) were stable on injections every 8 weeks or longer, and 36 patients (27%) required injections more frequently than every 8 weeks. Of the 27 patients who failed Avastin, 14 did not switch to another drug, and 13 were switched to aflibercept (Eylea, Regeneron).

Conclusions : Treatment of neovascular AMD with a regimen consisting of bevacizumab as first-line therapy is efficacious in the majority of patients.

This is a 2020 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×